KR101999916B1 - Composition for enhancement of muscular strength and preventing or treating of sarcopenia comprising Colpomenia bullosa extract - Google Patents

Abstract

The present invention relates to a composition for muscle strengthening or preventing and treating sarcopenia, containing a Colpomenia bullosa extract. More specifically, the present invention relates to: a pharmaceutical composition and a food composition for preventing, alleviating, or treating sarcopenia which have an effect of preventing and treating sarcopenia due to aging or muscle strengthening as the composition has an anti-myostatin activity; and a method for manufacturing the same.

Description

TECHNICAL FIELD [0001] The present invention relates to a composition for preventing or treating muscular weakness or muscular dystrophy,

The present invention relates to a composition for preventing or treating muscular dyspeptia or a composition for strengthening muscular power comprising the extract of Colpomenia bullosa, and more particularly, to a composition for enhancing muscular strength and aging- And a prophylactic and / or therapeutic agent for preventing or treating diabetes mellitus.

There have been two instances of doubling the population in the 20th century, but once in the 21st century it is difficult to double the population growth due to the declining fertility rate and the extension of the average life expectancy. According to the United Nations' 2015 World Population Prospects (2015 revision), the population over 60 years of age, which was 910 million people in 2015, will grow to about 1.4 billion in 2030 and reach 2.1 billion in 2050 Respectively. In addition, the number of elderly elderly people aged 80 or older will reach about 434 million by 2050, and this increase is expected to continue for decades to come. In 2000, the population aged 65 or older reached 7.2% of the total population in 2000, entered the aging society, and entered the aged society in 2018. In 2026, the proportion of the elderly population was 20.8% The National Statistical Office is expected to enter the post-aged society. Especially, it is pointed out that the period of reaching the aged society or the super aged society is very fast. This increase in the elderly population can lead to a decrease in productivity due to the decrease in the workforce, and the quality of life of the elderly can be lowered due to the decrease in physical strength due to aging.

Aging is a phenomenon in which the physical function of a living organism degrades with the passage of time. In humans, it is known that by age 80, hearing is reduced by 30%, blood release by 45%, vital capacity by 60% and muscle mass by 50% have. Various physiological activities due to aging are not lowered, and some enzymatic activity and hormone secretion function are also increased. Therefore, the physiological change due to aging is not a decrease in physiological activity, but a decrease in adaptive ability, since it is a deficiency of an objective function or a control mechanism.

A typical physiological change due to aging is muscle mass and muscle strength reduction. It is known that the decrease in muscle mass occurs from the 40s to the 70s, and the decrease is about 8% in 10 years. Thereafter, it is known that sudden decrease occurs up to 15% in 10 years. The sarcopenia of the elderly induces a direct decrease in muscle strength, thereby decreasing various body functions and increasing the risk of death due to the disorder, as well as decreasing the metabolism and decreasing the immunity, such as hypertension, diabetes, arthritis, obesity and cancer It may also increase the prevalence of metabolic diseases.

Accordingly, various therapeutic compositions capable of preventing or treating myopenia caused by aging have been actively studied, and in particular, there is a demand for development of novel materials having low side effects and high economic value.

Accordingly, the inventors of the present invention have confirmed that the long-boiled extract, which is a marine algae, has anti-myostatin activity, thus exhibiting the effects of strengthening muscle strength and preventing and treating muscular dystrophy.

Korean Patent Publication No. 10-2010-0116289

It is an object of the present invention to provide a composition for preventing and treating muscular dyspeptia comprising an extract of Colpomenia bullosa as an active ingredient.

Another object of the present invention is to provide a composition for strengthening muscle strength comprising an extract of Colpomenia bullosa as an active ingredient.

It is still another object of the present invention to provide a method for producing a fermented beverage, Concentrating the extract under reduced pressure to remove the solvent; And recovering the supernatant by centrifugation of the obtained long-term boiling extract. The present invention also provides a method for preparing a composition for preventing and treating muscle weakness and muscular dystrophy.

In order to solve the above-mentioned problems, the present invention provides a composition for preventing and treating muscular dyspeptia comprising an extract of Long Flour as an active ingredient.

The present invention also provides a composition for strengthening muscle strength comprising an extract of Long Flour as an active ingredient.

In one embodiment of the present invention, the composition is characterized in that it has an anti-carnitine activity, improves muscle strength and muscle density, and has an effect of increasing muscle mass.

In another embodiment of the present invention, the Long Flourescent Extract is an organic solvent extract, preferably water or an alcohol extract, more preferably an ethanol extract, but is not limited thereto.

In another aspect, the present invention provides a health functional food for preventing and alleviating myopenia, which comprises an extract of Long Flour as an active ingredient.

In another aspect, the present invention provides a health functional food for strengthening muscular strength comprising an extract of Long Flour as an active ingredient.

In another aspect, the present invention relates to a method for producing a fermented soybean curd; Concentrating the extract under reduced pressure to remove the solvent; And recovering the supernatant by centrifuging the obtained long term extract to obtain a composition for prevention or treatment of muscular dyspeptia or a composition for strengthening muscular strength.

In one embodiment of the present invention, the alcohol is added to the dried long flame, and the mixture is extracted at room temperature for 1 to 72 hours, but the present invention is not limited thereto.

Also, in one embodiment of the present invention, the preparation method includes, but is not limited to, dried gerbil regimen containing 10 to 30 mg / ml.

In another aspect, the present invention provides a pharmaceutical composition for preventing and treating muscular dyspeptia comprising the Long Flourescent Extract prepared by the above production method, or food for preventing and alleviating muscular dyspeptia.

The Long Flour Extract of the present invention has a high carnitine activity and has the effect of increasing muscle strength, muscle endurance and muscle mass, and as a result, it can be used for preventing, alleviating and treating geriatric muscle diseases such as myopenia .

FIG. 1 shows the results of a test for cytotoxicity according to the concentration of the long-term base extract of the present invention.
Fig. 2 shows the result of confirming antimyostatin activity of the long-boiled extract of the present invention through analysis of luciferase. (Phase: ethanol extract, bottom: hot water extract)
Fig. 3 shows experimental results confirming whether or not the actin A activity was inhibited by the long-boiled extract of the present invention.
FIG. 4 shows the results of an experiment to determine whether or not the Long Flour Extract of the present invention inhibits the activity of GDF11.
FIG. 5 shows the result of confirming the degree of phosphorylation of smad2 transcription factor through western blot in order to confirm the effect of the long-boiled extract of the present invention on myostatin signal transduction pathway.
FIG. 6 shows the results of oral administration of a long-boiled extract of the present invention to mice to determine whether or not the body weight was increased.
FIG. 7 shows the result of confirming whether or not the long-boiled extract of the present invention has an effect of actually increasing muscle strength by orally administering it to a mouse.
FIG. 8 shows the result of confirming whether or not the long-boiled extract of the present invention has an effect of increasing muscle density by orally administering to a mouse.

The present inventors have confirmed through experiments that effects of various natural materials such as inhibition of myostatin activity, muscle mass, and muscle density, etc., have been confirmed in order to select substances having a therapeutic effect on muscle strengthening and sarcopenia from natural materials, The inventors of the present invention have found that the extract obtained from the Long Fling term of the present invention has the above-mentioned effects and completed the present invention.

The Long Flame (Colpomenia bullosa) is a kind of algae belonging to the genus Scytosiphonaceae, Colpomenia. The thallus is yellowish brown with hollow cylinder, 1 ~ 3 pieces are gathered, and the length is 120mm and width is 35mm. The base is 20mm in diameter, and the root is attached to the rock. It grows from spring to autumn. It grows on the south coast, the west coast, the east coast, and Jeju. It is also distributed in Japan, China, New Zealand and Alaska to California ( http://www.kbr.go.kr , National Biodiversity Information Sharing System> Biological Resource DB)

The long term of the present invention is a dried sample. More specifically, after removing the salt and impurities from the seaweed, a solvent is added to the dried sample to extract at room temperature to obtain a crude extract, The extract can be prepared by concentration. The extraction method was extracted by conventional extraction method. The extraction method may be a cold extraction method, a hot extraction extraction method, a heat extraction method, or the like, and an ordinary extraction device or a fractionator may be used. In one embodiment of the present invention, an extract was prepared by extracting at room temperature without any additional heat treatment. After extracting for 24 hours with a solvent, all the solvent was recovered, and the sample was re-extracted with a fresh solvent again . This extraction process was repeated three times in total, and the extracted solvent was recovered and used.

The long term extraction solvent of the present invention may be an alcohol such as water, methanol or ethanol, an organic solvent or a mixture thereof, preferably 50% to 100% alcohol such as methanol, ethanol or the like having 1 to 4 carbon atoms , More preferably 80% to 100% ethanol. In one embodiment of the present invention, 100% ethanol was used, but the present invention is not limited thereto.

That is, the present invention relates to a composition for preventing and treating muscular dyspeptia comprising the above-mentioned Long Flour Extract as an active ingredient, and the composition includes a pharmaceutical composition and a food composition. It is known that sarcopenia is a disease caused by a decrease in skeletal muscle mass, and it directly causes a decrease in muscle strength, resulting in reduction of various body functions and disorder, and also increases the risk of death. This is a disease resulting from progressive skeletal muscle loss associated with aging (Park, Sungwon, 2007, Myopenia of the elderly, Journal of Endocrinology, Vol. 22, No. 1). In particular, the inventive Long Flourescent Extract has a therapeutic and prophylactic effect on myopenia by specifically inhibiting myostatin activity, which is a factor inhibiting the increase in muscle mass.

In addition, the present invention relates to a composition for improving muscle strength comprising the above-mentioned Long Flour Extract as an active ingredient, and the composition includes a health food composition or a food composition. The term " increase in muscle strength " refers to a phenomenon in which overall muscle strength is increased due to an increase in skeletal muscle amount or an improvement in muscle function, and does not mean a limited effect on a patient group of a specific disease.

In one embodiment of the present invention, it was confirmed that the Long Flourescent Extract of the present invention had antimyostatin activity. Myostatin is one of the transforming growth factor-β (TGF-β) superfamily and acts as an inhibitor of autocrine / paracrine which is very important for muscle growth AC McPherron, AM Lawler, SJ Lee, Nature, 387, 83-90, 1997). Myostatin is composed of 376 amino acids, and precursor proteins are activated by cleavage of two proteases. The first step is the cleavage of the 24-amino acid signal peptide by the purine family of enzymes. The next step is the cleavage by BMP1 / Tolloid matrix metalloproteinase resulting in the amino acid RSRR (Arg-Ser-Arg- Arg is cleaved to divide the N-terminal 27.04 kDa myostatin propeptide and the C-terminal 12.4 kDa (SJ Lee, Annu. Rev. Cell. Dev. Biol. , 61-86, 2004). Myostatin, which has mature activity, forms a dimer through the disulfide bond at the C-terminal site, which is 100% homologous to mice, rats, pigs, chickens, turkeys and dogs It is known.

It is known that the myostatin binds directly to the type 2 Aktivine receptor and also affects the Smad signaling mechanism. It is already known that when the activity of myostatin is inhibited, muscle differentiation is promoted and may play an important role in the improvement of various metabolic diseases. The present invention provides a pharmaceutical composition and a food composition containing a long-mature stem extract capable of modulating myostatin activity to improve symptoms of muscular diseases such as myopenia, and to strengthen muscle strength.

The pharmaceutical composition of the present invention may comprise a carrier, diluent, excipient or a combination of two or more thereof commonly used in biological preparations. The pharmaceutically acceptable carrier is not particularly limited as long as the composition is suitable for in vivo delivery, and can be used by mixing, for example, saline, sterilized water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, And other conventional additives such as antioxidants, buffers, and bacteriostats may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate into main dosage forms such as aqueous solutions, suspensions, emulsions, etc., pills, capsules, granules or tablets. In addition, the composition of the present invention may further contain one or more active ingredients showing the same or similar functions.

The composition of the present invention may be administered orally or non-orally (for example, intravenously, subcutaneously, intraperitoneally or topically) or peroral according to the desired method. The appropriate dosage of the pharmaceutical composition of the present invention may be determined depending on the patient's body weight, age, sex, health condition, diet, method of administration, administration time, administration method, excretion rate and severity of disease.

The food composition of the present invention has effects of preventing, treating or alleviating myopenia, or strengthening muscular strength, and includes foods, food additives, beverage or beverage additives. The food composition may further comprise suitable carriers, excipients and diluents conventionally used in the production thereof.

As used herein, the term " food " means a natural product or a processed product containing one or more nutrients. Preferably, it means that the food can be directly eaten through a certain degree of processing. Food, food additive, health functional food and beverage, preferably gum or candy.

Foods to which the composition of the present invention can be added include, for example, various foods, beverages, gums, candies, tea, vitamin complexes, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, natural flavors (eg, ramen soup, etc.), vitamin complexes, alcoholic beverages, alcoholic beverages and other health supplement foods. The food, beverage or food additive may be prepared by a conventional production method.

In the present invention, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques and the like, the regulation of the biological defense rhythm of the food composition, Refers to a food product which is processed by designing the body control function to be sufficiently expressed in living body. Preferably, it means a food which can sufficiently express the effect of preventing or alleviating myopenia or strengthening muscle strength. The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. These components can be used independently or in combination. The additive may be used in an amount of 0 to 20 parts by weight, preferably 0.00001 to 15 parts by weight, per 100 parts by weight of the antimicrobial composition of the present invention, but is not limited thereto.

In addition, the composition of the present invention may contain a long Flame-retarded extract at a concentration of 0.1 μg / ml to 100 μg / ml, more preferably 0.1 μg / ml to 10 μg / ml. If it is contained at a concentration of less than 0.1 μg / ml, the effect on mitigating the myopenia is insignificant. If it is contained at a concentration of 100 μg / ml or more, side effects such as inhibition of the activity of GDF11 belonging to the TGF- have.

Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited to these embodiments.

< Example  1>

Preparation of Long Flour Extract

The extracts were prepared by drying the collected long term pots. After removing the salt and impurities from the long-term flame, 100% ethanol was added to the dried sample to extract at a concentration of 20 mg / ml in a dark room at room temperature (25 ° C) for 24 hours. After 24 hours, the solvent was all recovered and the sample was re-extracted with fresh solvent. This extraction process was repeated three times in total, and the extracted solvent was recovered and used.

Further, in order to compare the effects, water of 90 占 폚 was used as a solvent and extracted for 20 minutes to prepare a hot-water extract of a long-boiled end.

The ethanol extract was concentrated under reduced pressure using a rotary vacuum concentrator, and centrifuged at 4000 rpm for 20 minutes to collect only the supernatant. The concentration of the recovered supernatant was measured using a centrifugal rotary evaporator, and it was confirmed that the extraction yield was about 4.6%.

It was confirmed that the water extract had an extraction yield of about 4.1%.

< Example  2>

Cytotoxicity check

In order to test the cytotoxicity of the extracted long-stemmed ethanol extract, Hek293 cells were divided into 1 × 10 ⁴ cells / 100 μl (in DMEM with 10% FBS and 1% penicillin / streptomycin) per well in a 96-well plate And cultured in a 5% CO ₂ incubator for 24 hours.

The long-term ethanol extracts were treated with the above-mentioned cultured cells at a concentration of 100 μg / ml, 10 μg / ml and 5 μg / ml, respectively, and cultured in a 5% CO ₂ incubator for 12 hours. After addition of 10 μl of WST reagent (DaeilLab, Korea), the reaction was allowed to proceed for 1 hour, and the absorbance was measured at 415 nm to determine cytotoxicity.

The results of cytotoxicity were compared by using the following equation as the positive control group and the negative control group as the H ₂ O ₂ -treated group.

Cell viability (%) =

As a result, as shown in Fig. 1, it was confirmed that the long-stemmed ethanol extract had less than 10% toxicity at all concentrations.

< Experimental Example  1> in vitro Long Flame Term  Check the effect of the extract

<1-1> Antimyostatin activity confirmation

Antimyostatin activity of long - term vinegar extract at cell level was confirmed by luciferase assay. Hek293 cells were cultured in DMEM medium (10% FBS, 1% penicillin / streptomycin, 1% geneticin) in a 96 well plate at 2.0 × 10 ⁴ cells / well in a 5% CO ₂ incubator. After 24 hours, the medium was replaced with DMEM in which FBS had been removed, and 1 μM recombinant myostatin (R & D system, USA) and long-term ethanol / hot-water extracts were added at 10 μg / / Ml and cultured in a CO ₂ incubator for 24 hours. After incubation, the medium was removed and the luminescence was measured in a microplate luminometer by treating 1: 1 with 65 μl of DMEM medium and 65 μl of reagent (Bright-Glo luciferase assay system, USA). The activity of hippocampal antioxidants was expressed as% using positive and negative control values.

As a result, as shown in FIG. 2, it was confirmed that the activity inhibitory effect on myostatin was increased in a concentration-dependent manner upon treatment with a long-term flourish extract. Antimyostatin activity was confirmed in both ethanol extracts and hot water extracts. Particularly, the ethanol extract of long-term flour was about 40 times higher than the IC50 value of 0.37 占 퐂 / ml (Fig. 2) and 14.40 占 퐂 / ml of long-stemmed hot-water extract (Fig. 2) .

<1-2> Confirmation of Actibin A / GDF11 Inhibition

Luciferase assays were performed in the same manner as myostatin in order to confirm that the anticholinergic regimen had inhibitory activity against actin A and GDF11 belonging to superfamily such as myostatin.

Hek293 cells cultured in the same manner as in 1-1 above were treated with 0.5 nM of actin A and 1 nM of GDF11, and 10 μg / ml, 1 μg / ml, 0.1 μg / ml And cultured in a CO ₂ incubator for 24 hours. After incubation, the medium was removed and the luminescence was measured in a microplate luminometer by treating 1: 1 with 65 μl of DMEM medium and 65 μl of reagent (Bright-Glo luciferase assay system, USA). Cell activity was expressed as% using positive and negative control values.

Figure 3 shows the inhibitory effect of Actibin A on activity. In the case of Actibin A, it was confirmed that there was no activity inhibitory effect by the long-term vinegar extract. Further, as shown in FIG. 4 for GDF11, it was found that the long-term flourishing extract inhibited the activity of GDF11 in a concentration-dependent manner. However, as a result of the experiment, it was confirmed that the IC50 value of GDF11 was 8.78 / / ㎖, which is much lower than the inhibitory activity against myostatin. (It is confirmed that it is 24 times higher than IC50 value.)

<1-3> Effect of myostatin on the signaling pathway

To confirm the effects of long-term flourish extract on the myostatin signaling pathway, Western blot analysis confirmed the degree of phosphorylation of smad2 transcription factor. The smad transcription factor is a receptor for signaling of the TGF-beta receptor to which myostatin belongs and plays an important role in cell growth and division. To perform Western blotting, HepG2 cells were cultured in a DMEM medium (10% FBS, 1% penicillin / streptomycin) in a 6-well plate at 2.0 × 10 ⁵ cells per well in a 5% CO ₂ incubator for 24 hours.

After 24 hours, the medium was replaced with DMEM in which the FBS had been removed, and the cells were further cultured for 4 hours. Then, 10 μM of recombinant myostatin and IC100 (94.56 μg / ml) and IC10 (0.28 μg / The extract was treated for 30 minutes. The cells were then washed twice with PBS and resuspended in RIPA buffer (20 mM tris-HCl, pH7.5, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium deoxychloate, 2.5 mM sodium (1 μg / ml leupeptin, cell signaling, USA) and protease inhibitor cocktail and phosphatase inhibitor cocktail (Roche, USA) were treated with 1 mM a-glycerophosphate, 1 mM NA3VO4,

After the treatment, the cells were disrupted using a sonicator and centrifuged at 4 ° C and 12,000 rpm for 20 minutes. The supernatant was quantitated by BCA assay and electrophoresed on 10% polyacrylamide gel. After electrophoresis, the cells were transferred to PVDF membrane and blocked with 5% BSA or 5% skim milk at room temperature for 2 hours. The membrane was washed three times with TBS-T buffer at room temperature for 10 minutes and then reacted with primary antibody (Samd2, P-Smad2, Cell signaling, USA) for 2 hours at room temperature.

Subsequently, the cells were washed three times for 10 minutes at room temperature with TBS-T buffer, and reacted for 2 hours at room temperature with a secondary antibody (anti-Rabbit IgG, Cell signaling, USA). Membrane was washed three times for 10 minutes at room temperature with TBS-T buffer and sensitized to x-ray film using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Scientific, USA).

As a result, as shown in Fig. 5, it was confirmed that the long Flame-retarded extract inhibited signal transduction inside the cell (phosphorylation of Smad transcription factor) by inhibiting myostatin signal transduction in a concentration-dependent manner. In FIG. 5, Lane 1 is control. Lane 2 was treated with only myostatin, indicating that the expression level of phosphorylated smad2 was increased. Lane 3 is a lane that simultaneously treated myostatin and SB431542 (a small molecule that inhibits the phosphorylation of receptors bound by myostatin) as a positive control, confirming that the amount of phosphorylated Smad2 expression, which should be increased by myostatin, is not increased I could. Lane 4 and 5 were lane treated with myostatin and long-stemmed termination extract. As in lane 4, almost no expression of phosphorylated smad2 was observed in lane 4, whereas expression of Smad2 was weakly observed in lane 5 . Based on these results, it was confirmed that the long - term vinegar extract inhibited signal transduction into cells by inhibiting the binding of myostatin to the receptor in a concentration - dependent manner.

< Experimental Example  2> in vivo  in Long Flame Term  Check the effect of the extract

In order to examine the effect of the long-stemming extract at the in vivo level on the muscle, ICR mice were orally administered to determine the changes in muscle strength and muscle endurance. Four-week-old male ICR mice were orally administered long-term flourish extracts once a day for 14 days. The injection amount was orally administered to the IC50 value (0.37 ug / ml) of 1 nM myostatin confirmed by luciferase assay once at 15 times (once dose of 5.55 / / ml). At the end of the experiment, body weight, muscle strength and muscle endurance test were performed at 0, 7, and 14 days after administration. The muscle density was calculated by measuring the weight and volume of the forelimb and hindlimb muscles and blood analysis was performed .

The mouse body weight was not significantly different from the control group for 14 days, but the muscle strength was significantly increased (p <0.001) at 9 days compared to the control group at 14 days (Fig. 6). Based on the mass and volume results of the forelimbs and hind legs, the muscle density increased significantly (p <0.05) compared to the control group (p <0.05) and the hindlimb was significantly increased by 3.9% ) (Fig. 7).

The present invention has been described with reference to the preferred embodiments. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims. Therefore, the disclosed embodiments should be considered in an illustrative rather than a restrictive sense. The scope of the present invention is defined by the appended claims rather than by the foregoing description, and all differences within the scope of equivalents thereof should be construed as being included in the present invention.

Claims (17)

A composition for preventing and treating muscular dystrophy comprising an extract of Colpomenia bullosa as an active ingredient. The method according to claim 1,
Wherein the composition has anti-myostatin activity. The method according to claim 1,
Wherein the composition improves muscle strength and muscle density. The method according to claim 1,
Wherein the composition has an effect of increasing muscle mass. The method according to claim 1,
The composition for preventing and treating muscular dystrophy according to claim 1, wherein the long-term base extract is water or an alcohol extract. The composition according to claim 1, wherein the composition is a pharmaceutical composition. A health functional food for preventing and alleviating myopenia, comprising the extract of Colpomenia bullosa as an active ingredient. A composition for strengthening muscle strength comprising an extract of Colpomenia bullosa as an active ingredient. A health functional food for strengthening muscle strength comprising the composition of claim 8. (a) adding a solvent to a dried long flame;
(b) concentrating the extract at a reduced pressure to remove the solvent; And
(c) centrifuging the long bead extract obtained in (b) above to recover the supernatant. [10] The method of claim 10, wherein the solvent of step (a) is water or ethanol. 12. The method of claim 11, wherein the ethanol is extracted at room temperature when the ethanol is used as a solvent. [10] The method of claim 10, wherein the extraction of step (a) is performed for 1 to 24 hours, and repeated for 1 to 3 times. [10] The method according to claim 10, wherein the step (a) comprises a concentration of 10 to 30 mg / ml. 14. A pharmaceutical composition for preventing and treating myopenia, which comprises an extract of Long Floures which has been extracted by the method of any one of claims 10 to 14. 14. A food for preventing and alleviating myopenia, comprising a long-boiled extract obtained by the method according to any one of claims 10 to 14. 14. A muscle-strengthening food comprising a long-boiled extract obtained by the method of any one of claims 10 to 14.

Images